eRAM
encyclopedia of Rare Disease Annotation for Precision Medicine
| Disease | carcinoid syndrome |
| Comorbidity | C0206754|neuroendocrine tumors |
| Sentences | 7 |
| PubMedID- 25824001 | Background/aims: the phase iii placebo-controlled radiant-2 trial investigated the efficacy of everolimus plus octreotide long-acting repeatable (lar) in patients with advanced neuroendocrine tumors (net) associated with carcinoid syndrome. |
| PubMedID- 21279821 | Functional tumors are commonly associated with a specific hormonal syndrome directly related to a hormone secreted by the tumor, like gastrinomas with a zollinger-ellison syndrome or carcinoid syndrome in patients with neuroendocrine tumors (net) of the ileum. |
| PubMedID- 26431405 | Placebo (pbo) for carcinoid syndrome (cs) in patients with neuroendocrine tumors (nets): subgroup analysis of the elect study. |
| PubMedID- 24144293 | neuroendocrine tumors presenting with the carcinoid syndrome and their cardiovascular manifestations are also discussed. |
| PubMedID- 24403259 | The targeted cancers were hormone-receptor-positive advanced breast cancer, advanced neuroendocrine tumors associated with carcinoid syndrome, advanced renal cell carcinoma, and advanced pancreatic neuroendocrine tumor. |
| PubMedID- 26315553 | Background: octreotide long-acting repeatable (lar) is approved in the united states for the management of carcinoid syndromes among patients with neuroendocrine tumors (net). |
| PubMedID- 24213466 | Those synthetic analogues of the peptide hormone somatostatin, octreotide and lanreotide (also in case of inoperable carcinoids), are being the most widely used ones in controlling carcinoid syndrome with metastatic well-differentiated neuroendocrine tumors and are still debated [3,19,22]. |
Page: 1